IRLAB Therapeutics AB (publ) board of directors has appointed Richard Godfrey as the new CEO. Richard will take up the new position on 1 July 2022. Richard Godfrey, b. 1966, has over 25 years experience of leadership positions in the life science industry in the USA, the Nordic countries and the United Kingdom.

Richard was CEO of the listed biotech company BerGenBio ASA for 12 years and most recently the chief operating officer at LifeArc. Richard Godfrey holds a bachelor's degree in pharmaceutical chemistry from the University of Liverpool, an MBA from the University of Bath and is a member of The Royal Pharmaceutical Society of Great Britain.